NCT00770588 - Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

296

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

February 28, 2011

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Gefitinib

Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD

DRUG

Placebo

To match Gefitinib

Trial Locations (14)

Research Site, Beijing

Research Site, Fuzhou

Research Site, Guangzhou

Research Site, Nanning

Research Site, Zhengzhou

Research Site, Wuhan

Research Site, Nanjing

Research Site, Changchun

Research Site, Shengyang

Research Site, Shanghai

Research Site, Xi’an

Research Site, Chengdu

Research Site, Tianjin

Research Site, Hangzhou